|
1
|
El-Serag HB: Hepatocellular carcinoma: An
epidemiologic view. J Clin Gastroenterol. 35:S72–S78.
2002.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Falade-Nwulia O, Suarez-Cuervo C, Nelson
DR, Fried MW, Segal JB and Sulkowski MS: Oral direct-acting agent
therapy for hepatitis c virus infection: A systematic review. Ann
Intern Med. 166:637–648. 2017.PubMed/NCBI View
Article : Google Scholar
|
|
3
|
Blüher M: Obesity: Global epidemiology and
pathogenesis. Nat Rev Endocrinol. 15:288–298. 2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Mittal S and El-Serag HB: Epidemiology of
hepatocellular carcinoma: Consider the population. J Clin
Gastroenterol. 47 (Suppl):S2–S6. 2013.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Tateishi R, Uchino K, Fujiwara N, Takehara
T, Okanoue T, Seike M, Yoshiji H, Yatsuhashi H, Shimizu M, Torimura
T, et al: A nationwide survey on non-B, non-C hepatocellular
carcinoma in Japan: 2011–2015 update. J Gastroenterol. 54:367–376.
2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Sanyal A, Poklepovic A, Moyneur E and
Barghout V: Population-based risk factors and resource utilization
for HCC: US perspective. Curr Med Res Opin. 26:2183–2191.
2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Younossi ZM, Koenig AB, Abdelatif D, Fazel
Y, Henry L and Wymer M: Global epidemiology of nonalcoholic fatty
liver disease-Meta-analytic assessment of prevalence, incidence,
and outcomes. Hepatology. 64:73–84. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kokudo N, Takemura N, Hasegawa K, Takayama
T, Kubo S, Shimada M, Nagano H, Hatano E, Izumi N, Kaneko S, et al:
Clinical practice guidelines for hepatocellular carcinoma: The
Japan society of hepatology 2017 (4th JSH-HCC guidelines) 2019
update. Hepatol Res. 49:1109–1113. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
European Association for the Study of the
Liver. Electronic address: simpleeasloffice@easloffice.eu;
European Association for the Study of the Liver. EASL clinical
practice guidelines: Management of hepatocellular carcinoma. J
Hepatol. 69:182–236. 2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Heimbach JK, Kulik LM, Finn RS, Sirlin CB,
Abecassis MM, Roberts LR, Zhu AX, Murad MH and Marrero JA: AASLD
guidelines for the treatment of hepatocellular carcinoma.
Hepatology. 67:358–380. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Karagozian R, Derdák Z and Baffy G:
Obesity-associated mechanisms of hepatocarcinogenesis. Metabolism.
63:607–617. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hiraoka A, Kumada T, Michitaka K and Kudo
M: Newly proposed ALBI grade and ALBI-T score as tools for
assessment of hepatic function and prognosis in hepatocellular
carcinoma patients. Liver Cancer. 8:312–325. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Sumida Y, Yoneda M, Hyogo H, Itoh Y, Ono
M, Fujii H, Eguchi Y, Suzuki Y, Aoki N, Kanemasa K, et al:
Validation of the FIB4 index in a Japanese nonalcoholic fatty liver
disease population. BMC Gastroenterol. 12(2)2012.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Angulo P, Hui JM, Marchesini G, Bugianesi
E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, et
al: The NAFLD fibrosis score: A noninvasive system that identifies
liver fibrosis in patients with NAFLD. Hepatology. 45:846–854.
2007.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Tokushige K, Ikejima K, Ono M, Eguchi Y,
Kamada Y, Itoh Y, Akuta N, Yoneda M, Iwasa M, Yoneda M, et al:
Evidence-based clinical practice guidelines for nonalcoholic fatty
liver disease/nonalcoholic steatohepatitis 2020. Hepatol Res.
51:1013–1025. 2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Chalasani N, Younossi Z, Lavine JE, Diehl
AM, Brunt EM, Cusi K, Charlton M and Sanyal AJ: The diagnosis and
management of non-alcoholic fatty liver disease: Practice guideline
by the American association for the study of liver diseases,
American college of gastroenterology, and the American
gastroenterological association. Hepatology. 55:2005–2023.
2012.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Francque SM, Marchesini G, Kautz A,
Walmsley M, Dorner R, Lazarus JV, Zelber-Sagi S, Hallsworth K,
Busetto L, Frühbeck G, et al: Non-alcoholic fatty liver disease: A
patient guideline. JHEP Rep. 3(100322)2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Tokushige K, Ikejima K, Ono M, Eguchi Y,
Kamada Y, Itoh Y, Akuta N, Yoneda M, Iwasa M, Yoneda M, et al:
Evidence-based clinical practice guidelines for nonalcoholic fatty
liver disease/nonalcoholic steatohepatitis 2020. J Gastroenterol.
56:951–963. 2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Yoshida H, Shiratori Y, Moriyama M,
Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, et
al: Interferon therapy reduces the risk for hepatocellular
carcinoma: National surveillance program of cirrhotic and
noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study
group. inhibition of hepatocarcinogenesis by interferon therapy.
Ann Intern Med. 131:174–181. 1999.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Shiratori Y, Imazeki F, Moriyama M, Yano
M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G,
et al: Histologic improvement of fibrosis in patients with
hepatitis C who have sustained response to interferon therapy. Ann
Intern Med. 132:517–524. 2000.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Xiao G, Zhu S, Xiao X, Yan L, Yang J and
Wu G: Comparison of laboratory tests, ultrasound, or magnetic
resonance elastography to detect fibrosis in patients with
nonalcoholic fatty liver disease: A meta-analysis. Hepatology.
66:1486–1501. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Imai K, Takai K, Miwa T, Maeda T, Hanai T,
Shiraki M, Suetsugu A and Shimizu M: Increased visceral adipose
tissue and hyperinsulinemia raise the risk for recurrence of Non-B
Non-C hepatocellular carcinoma after curative treatment. Cancers
(Basel). 13(1542)2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Imai K, Takai K, Maeda T, Watanabe S,
Hanai T, Suetsugu A, Shiraki M and Shimizu M: Increased visceral
fat volume raises the risk for recurrence of hepatocellular
carcinoma after curative treatment. Oncotarget. 9:14058–14067.
2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Imai K, Takai K, Hanai T, Suetsugu A,
Shiraki M and Shimizu M: Homeostatic model assessment of insulin
resistance for predicting the recurrence of hepatocellular
carcinoma after curative treatment. Int J Mol Sci.
20(605)2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Suzuki Y, Imai K, Takai K, Hanai T,
Hayashi H, Naiki T, Nishigaki Y, Tomita E, Shimizu M and Moriwaki
H: Hepatocellular carcinoma patients with increased oxidative
stress levels are prone to recurrence after curative treatment: A
prospective case series study using the d-ROM test. J Cancer Res
Clin Oncol. 139:845–852. 2013.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Watanabe N, Takai K, Imai K, Shimizu M,
Naiki T, Nagaki M and Moriwaki H: Increased levels of serum leptin
are a risk factor for the recurrence of stage I/II hepatocellular
carcinoma after curative treatment. J Clin Biochem Nutr.
49:153–158. 2011.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Fluss R, Faraggi D and Reiser B:
Estimation of the Youden Index and its associated cutoff point.
Biom J. 47:458–472. 2005.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Cao L, Cheng H, Jiang Q, Li H and Wu Z:
APEX1 is a novel diagnostic and prognostic biomarker for
hepatocellular carcinoma. Aging (Albany NY). 12:4573–4591.
2020.PubMed/NCBI View Article : Google Scholar
|
